Diabetic Retinopathy and Skin Tissue Advanced Glycation End Products Are Biomarkers of Vascular Events in Type 2 Diabetic Patients

Alejandra Planas
  Vall d'Hebron Hospital: Vall d'Hebron Hospital Universitari

Olga Simó-Servat
  Vall d'Hebron Hospital: Vall d'Hebron Hospital Universitari

Cristina Hernández
  Vall d'Hebron Research Institute: Vall d'Hebron Institut de Recerca

Ángel Ortiz-Zúñiga
  Vall d'Hebron University Hospital: Vall d'Hebron Hospital Universitari

Joan Ramón Marsal
  Vall d'Hebron Research Institute: Vall d'Hebron Institut de Recerca

José Raul Herance
  Vall d'Hebron Research Institute: Vall d'Hebron Institut de Recerca

Ignacio Ferreira-González
  Vall d'Hebron Hospital: Vall d'Hebron Hospital Universitari

Rafael Simó (rafael.simo@vhir.org)
  Vall d'Hebron Research Institute

Original investigation

Keywords: Advanced glycation end products, Diabetic retinopathy, prospective case control study, Type 2 diabetes, vascular events.

Posted Date: September 27th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-895697/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

BACKGROUND AND AIMS: Vascular events are the main cause of mortality in patients with type 2 diabetes. However, the risk of vascular events is not homogeneous in subjects with type 2 diabetes and, therefore, an early identification of patients at high risk of developing vascular events remains a challenge to be met. The aim of this study is to evaluate whether the presence of diabetic retinopathy (DR) and accumulation of advanced glycation end products (AGEs) in subcutaneous tissue can help to identify those patients at high risk of vascular events.

MATERIAL AND METHODS: It was a prospective study comprising 200 subjects with type 2 diabetes with no history of clinical cardiovascular disease and 60 non-diabetic controls, matched by age and sex (PRECISED study: ClinicalTrials.gov NCT02248311). The inclusion period began on September 2014 and finished on June 2017. We collected basal features of the subjects, classical cardiovascular risk factors (i.e. age, sex, hypertension, dyslipidemia and coronary artery calcium score [CACs]), presence and degree of DR, and the accumulation of AGEs in subcutaneous tissue using the AGE readerTM device (DiagnOptics Technologies). We followed these subjects until December 2020, collecting any coronary, cerebrovascular or peripheral arterial event.

RESULTS: After a follow up of 4.35 ± 1.43 years, a total of 24 vascular events were registered. There was no significant difference regarding age and gender between individuals with type 2 diabetes and the control group. The number of vascular events was higher in type 2 diabetes group than in the control group (12.3% vs. 1.75%). When analysing the risk factors we found that apart from classic risk factors such as age, gender and CACs, subjects with type 2 diabetes and vascular events presented a higher prevalence of DR (47.8% vs. 24.4%; p = 0.018) and AGEs in subcutaneous tissue (63.15% vs 26.71% of values in the higher tertile, p = 0.001). DR and AGEs in subcutaneous tissue remain as independent variables related to the development of vascular events in the Cox proportional hazard multiple regression analysis (HR 2.58, 95%CI 1.14–5.85, p = 0.023, and HR 4.68, 95%CI 1.83–11.96, p = 0.001; respectively).

CONCLUSIONS: As we expected, patients with type 2 diabetes have significantly more VE than non-diabetic subjects. Apart from the classic factors such as age, sex and CACs, we observed that the presence of DR and high levels of AGEs in subcutaneous tissue were predictors of vascular events.

Introduction

Type 2 diabetes confers a substantial burden of macrovascular disease, with two-to four-fold higher increased risk of any cardiovascular event in comparison with non-diabetic patients (1, 2). Although type 2 diabetes is recognized as an independent risk factor for cardiovascular disease (CVD), not all patients with diabetes appear to be at equal risk. In fact, a high percentage of these patients will never experience vascular complications (3, 4). Therefore, the early identification of diabetic patients at risk of developing CVD remains as a challenge to be met (5, 6).
It is well known that chronic hyperglycaemia is related with vascular complications of diabetes. However, two large studies revealed that tight glucose control slightly but no significantly reduced the risk of cardiovascular disease (CVD) in either type 1 (7) or type 2 diabetes patients (8). Furthermore, the exaggerated risk for CVD in this population is not fully explained by conventional risk factors such as obesity, hyperglycaemia, dyslipidaemia and hypertension and, in fact, a substantial proportion of this risk remains unexplained (5, 6). Therefore, specific diabetes-related risk factors should be involved in the excess risk for CVD, and tissue accumulation of advanced glycation end products (AGEs) could be one of them.

AGEs are formed by the Maillard process, a non-enzymatic glycation of proteins. Early-stage reactions lead to formation of the early glycation adducts (as HbA1c), and later-stage reactions subsequently form AGEs (9). AGEs accumulate in the body during aging, and this process is accelerated by chronic hyperglycemia and oxidative stress (10), two conditions commonly present in type 2 diabetes. Therefore, the formation and accumulation of AGEs is accelerated by the diabetic milieu.

AGEs may play a critical role in the development of diabetic complication by two pathways. First, AGEs can form cross-links with proteins that affect the three-dimensional structure and thereby the functions of these proteins, for example collagen; its modification leads to an increase in vascular and myocardial stiffness. Second, AGEs can cause deleterious effects by the activation of receptors for AGEs (RAGEs), which in turn can lead to activation of second messengers and transcription factors that up-regulate pro-inflammatory cytokines and mediators of oxidative stress. These effects modify pathways which contribute to vascular dysfunction and accelerated development of atherosclerotic processes (11).

In recent years, it has been developed a simple and non-invasive method for AGEs assessment through skin autofluorescence (SAF) based on specific fluorescence of some AGEs. SAF has a strong correlation with the specific AGEs content in skin biopsies, as shown by validation studies (12, 13). There is accumulating evidence of the relationship between SAF and the presence of micro and macroangiopathy in individuals with type 2 diabetes (14). We had previously reported that SAF was a good predictor of a calcium score (CACs) > 400AU, a reliable marker of coronary atherosclerosis (15).

Emerging data indicates link between diabetic microvascular complications such as retinopathy, nephropathy and neuropathy, and cardiovascular disease (16, 17). In addition, a population-based cohort study showed that cumulative burden of microvascular disease increases the risk of future CVD among individuals with type 2 diabetes (18). DR has been linked with an increase in risk for all-cause and cardiovascular mortality in patients with diabetes (19, 20). The degree of DR is related to several classical cardiovascular risk factors including hyperglycaemia, blood pressure, renal insufficiency, etc. In addition, we provide evidence that the presence and the degree of DR was a powerful and independent risk factor for identifying subjects with subclinical CVD (21). It should be noted that the diabetic-induced microvascular abnormalities that occurs in the retina may also happen in other vascular beds, such as myocardial microcirculation (22, 23). Nevertheless, DR is often missing as a risk factor in studies addressed to evaluate CVD.
On this basis, the aim of this study is to evaluate whether the presence of diabetic retinopathy (DR) and accumulation of advanced glycation end products (AGEs) in subcutaneous tissue can help to identify those patients with type 2 diabetes at high risk of developing vascular events.

**Material And Methods**

**Study design and subjects**

It was a prospective case-control study comprising 200 subjects with type 2 diabetes and 60 non-diabetic controls matched by age and sex, all of them with no history of clinical CVD. The included subjects were enrolled in the PRECISED study (ClinicalTrials.gov NCT02248311).

All subjects enrolled must meet the following criteria: 1) type 2 diabetes diagnosed at least one year before to the day of screening; b) Age from 50–79 years; c) No history of vascular event; d) No contraindication for the performance of CT scan or SAF assessment; and e) No concomitant disease associated with a short life expectancy.

All included subjects were selected from the Outpatient Diabetic Clinic of Vall d’Hebron University Hospital and the Primary Healthcare centers within its catchment area (North Barcelona). The recruitment period began on September 2014 and finished on June 2017. Of the 200 patients with type 2 diabetes, 13 withdrawn the consent, and the same occurred in 3 out 60 of the control group. Consequently, 187 subjects with type 2 diabetes and 57 non-diabetic controls were followed until December 2020.

The study was conducted according to the declaration of Helsinki and was approved by the local ethics committee. All subjects provided written informed consent before study entry.

**Data collection and laboratory tests**

Basal features of the subjects and classical cardiovascular risk factors (age, sex, ethnicity, current smoking, body mass index, systolic and diastolic blood pressure, clinical characteristic of diabetes disease and comorbidities associated) were collected at the first visit. In addition, a fasting venous blood sample was obtained from each recruited patient.

Anthropometric data were obtained by standardized protocols. A balance with a fixed stadiometer was used to measure height and weight. Waist circumstance was measured between the 10th rib and the iliac crest.

The assessment of the classic risk factors was carried out as follows: A history of smoking habits (non-smoker/current smoker/ex-smoker) was recorded. Hypertension was established as systolic blood pressure $\geq 140$ mm Hg or diastolic blood pressure $\geq 90$ mm Hg, or when subjects were under treatment with antihypertensive agents. Dyslipidaemia was defined by the use of lipid-lowering drugs, decreased values of high-density lipoprotein (HDL) cholesterol (men < 0.9mmol/L, women < 1mmol/L), or by at least
one increased value of total cholesterol (> 5.2mmol/L), low-density lipoprotein (LDL) cholesterol (> 4.3mmol/L), or triglycerides (> 1.7mmol/L)

Fasting venous blood sample was collected from the antecubital vein, separated by centrifugation (2000xg at 4°C for 20 min) and frozen at – 80°C for batched storage and analysis. HbA1c was by the Cobas B 101 (Roche) system. The remaining biochemical parameters were measured using an Olympus AU5400 automatic biochemistry analyzer (Olympus, Tokyo, Japan).

**Fundus Eye examination**

DR was evaluated by experienced ophthalmologists in mydriasis using slit-lamp biomicroscopy and retinography with the same camera (Topcon-DRI-OCTTRITON). The examiners classified DR according to the International Clinical Diabetic Retinopathy Disease Severity Scale (24): (1) no apparent retinopathy, (2) mild non-proliferative retinopathy (NPDR), (3) moderate NPDR, (4) severe NPDR, and (5) proliferative diabetic retinopathy (PDR).

**Measurement of Skin Autofluorescence**

SAF was measured using the AGE Reader™ (DiagnOptics TechnologiesBV, Groningen, the Netherlands), a non-invasive desktop device. AGE ReaderTM detects the characteristic fluorescence of some AGEs and was used to estimate the level of AGEs in the skin. Technical and optical details of this non-invasive method have been described more extensively elsewhere (12). In short, the AGE ReaderTM illuminates a skin surface of 4cm² guarded against surrounding light, and uses an excitation light source with a peak excitation of 370. Subsequently, the emitted fluorescence light (within the wavelength range of 420–600 nm) and the reflected excitation light (within the wavelength range of 300–420 nm) from the skin are measured with a spectrometer. SAF is calculated in arbitrary units (AU) as the ratio between the emitted light and the reflected light, multiplied by 100. A series of 3 consecutive measurements was carried out, taking less than a minute. The mean SAF was calculated from these 3 measurements on the ventral side of the forearm and these. We create a variable according SAF value in this population (Higher or Lower SAF): Higher SAF included 3rd tertile SAF values, while lower SAF included 1st and 2nd tertile SAF values.

**CT-CAC scanning**

First, patient was prepared with beta blockers to decrease the heart rate, and nitroglycerin for vasodilatation if needed, then an ECG synchronized prospective contrast-enhanced coronary CT was performed with SiemensBiograph mCT 64s equipment. Automatic coronary vessel extraction of all coronary vessels with visual analysis of coronary stenosis was performed by researchers’ blind to the patient’s condition with “Syngo.Via” cardiac CT software as described elsewhere (25). The subjects were divided into two groups according their CACs: CAC < 400 AU and CAC > 400 AU. A value of CACs ≥ 400 AU was considered as “high coronary risk”.

**Outcome**
The primary outcome was the time to first vascular event. We defined vascular event as a composite of myocardial infarction, coronary revascularization, stroke, lower limb amputation or cardiovascular death.

**Statistical analysis**

Quantitative variables were expressed as the mean ± standard deviation (SD) except for triglycerides, homocysteine and lipoprotein(a) in which median and range were used due to their skewed distribution. Categorical variables were expressed as the absolute number (percentage). Differences among groups were performed using the Student’s t test for quantitative variables with a normal distribution and the Pearson’s chi-squared test for categorical variables. Non-parametric tests were used for those quantitative variables without normal distribution. In view of the skewed distribution of CACs values they were logarithmically converted to use parametric tests. We used the Kaplan-Meier method to create vascular event free survival and the log-likelihood test to examine differences in survival.

The differences between diabetic subjects who presented a vascular event and those without it were assessed. Cox proportional hazard multiple regression analysis was used to determine independent predictors of vascular events during the follow-up period. The model included all variables that showed association with vascular events in univariate analysis with a p value < 0.05. ROC curves were calculated and the $\chi^2$ test for ROC area comparison was performed. Statistical analyses was performed with Stata statistical package 15. Significance was accepted at the level of $p < 0.05$ for all the analyses.

**Results**

**Basal characteristics of the sample**

The clinical characteristics and the main laboratory findings of both groups (type 2 diabetes and controls) and the specific characteristics of subjects with type 2 diabetes are shown in Table 1. We did not find any significant differences between groups regarding age, gender, ethnicity, smoking habit or family history of cardiovascular disease. The specific characteristics of subjects with type 2 diabetes are shown in Table 2. Individuals with type 2 diabetes included in the study had a relative good metabolic control (HbA1c 56 ± 8.9mmol/mol (7.4 ± 1.18%)) and exhibited a long-term duration of the disease (14 ± 9.4y). More than a half of patients with type 2 diabetes were under treatment with insulin alone or in combination with antidiabetic agents. Regarding microangiopathic complications: 26.73% had DR, 33.9% had urine albumin/creatinine ratio >3.39mg/mmol, and 18.37% had clinical neuropathy.
Table 1
Characteristics of subjects with type 2 diabetes and non-diabetic control subjects

|                                | Type 2 diabetes (n = 187) | Control group (n = 57) | P     |
|--------------------------------|----------------------------|------------------------|-------|
| Sex (woman) (n,% )             | 108 (57.75%)               | 37 (64.91%)            | 0.33  |
| Ethnicity (Caucasian n,% )     | 179 (95.72%)               | 56 (98.25%)            | 0.65  |
| Age (years)                    | 65.63 ± 6.52               | 66.01 ± 6.63           | 0.85  |
| BMI (kg/m²)                    | 30.23 ± 4.89               | 26.83 ± 3.11           | < 0.001|
| Waist circumference (cm)       | 103.9 ± 13.53              | 91.2 ± 13.92           | < 0.001|
| Smoking                        |                            |                        |       |
| No (n,% )                      | 99 (48.13%)                | 34 (59.65%)            | 0.59  |
| Current Smoker (n, %)          | 62 (33.15%)                | 15 (26.32%)            |       |
| Ex-smoker (n, %)               |                            |                        |       |
| CV family history (n, %)       | 22 (11.76%)                | 8 (14.04%)             | 0.65  |
| Hypertension (n, %)            | 135 (71.19%)               | 28 (49.12%)            | 0.001 |
| Use of ACEi/ARB (n, %)         | 118 (63.1%)                | 18 (31.58%)            | < 0.001|
| Dyslipidemia (n, %)            | 149 (79.67%)               | 25 (43.86%)            | < 0.001|
| Use of statins (n,% )          | 133 (71.51%)               | 19 (31.67%)            | < 0.001|
| Use of ezetimibe (n,% )        | 10 (5.38%)                 | 0                      | 0.074 |
| Total cholesterol (mmol/L)     | 4.78 ± 0.92                | 5.57 ± 0.91            | < 0.001|
| HDL cholesterol (mmol/L)       | 1.28 ± 0.32                | 1.28 ± 0.29            | < 0.001|
| LDL cholesterol(mmol/L)        | 2.72 ± 0.78                | 3.43 ± 0.81.14         | < 0.001|
| Triglycerides (mmol/L)         | 1.73 [0.50–5.67]           | 1.24 [0.46–5.27]       | 0.012 |
| HbA1c (mmol/mol)               | 56.33 ± 9.01               | 42.02 ± 3              | < 0.001|
| HbA1c (%)                      | 7.44 ± 1.19                | 5.55 ± 0.31            | < 0.001|
| Creatinine (mmol/l)            | 0.725 ± 0.021              | 0.067 ± 0.017          | 0.075 |
| GFR ml/min                     | 81.76 ± 16.00              | 85.57 ± 10.88          | 0.09  |
| AST (UI/L)                     | 25.51 ± 15.71              | 23.48 ± 5.73           | 0.34  |
| ALT (UI/L)                     | 25.94 ± 16.88              | 21.12 ± 10.55          | 0.043 |
| GGT (UI/L)                     | 44.46 ± 71.82              | 31.04 ± 29.77          | 0.17  |
Table 2
Diabetes features and comorbidities in type 2 diabetes subjects

|                          | Type 2 diabetes (n = 187) | Control group (n = 57) | P   |
|--------------------------|---------------------------|------------------------|-----|
| Skin AF (AU)             | 2.68 ± 0.65               | 2.41 ± 0.60            | 0.001|
| Log CACs                 | 2.11 ± 0.81               | 1.59 ± 0.72            | 0.002|
| CCsA ≥ 400 AU (n, %)     | 41 (21.93%)               | 0                      | < 0.001|

Follow-up

187 subjects with type 2 diabetes and 57 non-diabetic controls were followed until December 2020. After a follow up of 4.35 ± 1.43 years, a total of 24 vascular events were registered, 23 vascular events (12.3%)
in type 2 diabetes group, and 1 (1.75%) in non-diabetic control group. The Kaplan-Meier analysis shows vascular event free-survival regarding groups (p = 0.031), (Fig. 1).

In our type 2 diabetes cohort we found an incidence rate of vascular events of 28.27 per 1000 persons-years. The main basal clinical characteristics of patients with type 2 diabetes according the presence of primary outcome (first vascular event) are shown on Table 3. The multivariate Cox’s regression (Table 4) including selected variables that were significant at the univariate analyses and known risk factors of CVD, showed that only age (HR 1.09, 95%CI 1.01–1.18, p = 0.024), gender (HR 0.35, 95%CI 0.15–0.83, p = 0.0174), the presence of retinopathy (HR 2.58, 95%CI 1.14–5.85, p = 0.023), CACS > 400AU (HR 4.16, 95%CI 1.14–10.26, p = 0.002), and a value of SAF on 3rd tertile (HR 4.68, 95%CI 1.83–11.96, p = 0.001) were independently associated with the presence of vascular event.
Table 3
Clinical characteristics of patients with type 2 diabetes according the presence of primary outcome (first vascular event)

|                                | Vascular event + (n = 23) | Vascular event - (n = 164) | p    |
|--------------------------------|---------------------------|----------------------------|------|
| Follow up (y)                  | 5.09 ± 1.20               | 5.21 ± 0.95                | 0.564|
| Sex (woman) (n, %)             | 8 (34.7%)                 | 100 (60.9%)                | 0.017|
| Age (years)                    | 68.61 ± 6.04              | 65.22 ± 6.49               | 0.019|
| BMI (kg/m²)                    | 30.18 ± 4.19              | 30.23 ± 4.99               | 0.961|
| Diabetes duration (years)      | 17.69 ± 9.44              | 14.08 ± 9.34               | 0.084|
| Waist circumference (cm)       | 105.6 ± 11.89             | 103.69 ± 13.7              | 0.552|
| Smoking                        |                           |                            |      |
| No (n, %)                      | 11 (47.8%)                | 88 (53.65%)                | 0.943|
| Current smoker (n, %)          | 03 (13.04%)               | 22(13.41%)                 |      |
| Ex-smoker (n, %)               | 08(34.37%)                | 55(33.53%)                 |      |
| Hypertension (n, %)            | 17 (73.9%)                | 118 (71.9%)                | 0.844|
| Dyslipidemia (n, %)            | 16 (69.76)                | 133 (81.1%)                | 0.198|
| Insulin treatment (n,%)        | 17 (73.9%)                | 91 (54.48%)                | 0.198|
| Fast plasma glucose (mmol/L)   | 7.99 ± 2.43               | 8.73 ± 2.79                | 0.232|
| HbA1c (mmol/mol)               | 58.45 ± 8.10              | 56.1 ± 9.08                | 0.234|
| HbA1c (%)                      | 7.72 ± 1.07               | 7.41 ± 1.20                | 0.234|
| Total cholesterol (mmol/L)     | 4.69 ± 0.66               | 4.78 ± 0.95                | 0.682|
| HDL cholesterol (mmol/L)       | 1.33 ± 0.38               | 1.27 ± 0.30                | 0.399|
| LDL cholesterol (mmol/L)       | 2.73 ± 0.47               | 2.71 ± 0.82                | 0.906|
| Triglycerides (mmol/L)         | 1.39[0.51–2.5]            | 1.53 [0.6–5.7]             | 0.046|
| Homocysteine (μmol/L)          | 12.5 [8.1–17.4]           | 11.3 [5.8–127]             | 0.765|
| Lipoprotein (a) (mg/dl)        | 7.21 [1–91.2]             | 8.45 [1–162.9]             | 0.745|
| GFR (ml/min)                   | 86.5 ± 11.18              | 81.12 ± 16.46              | 0.285|
| Creatinine (mmol/l)            | 0.068 ± 0.01              | 0.0734 ± 0.02              | 0.278|
|                                      | Vascular event + (n = 23) | Vascular event - (n = 164) | p   |
|--------------------------------------|---------------------------|-----------------------------|-----|
| Albumin/creatinine ratio             | 9 (40.9%)                 | 111 (68.5%)                 | 0.06|
| <3.39 mg/mmol (n, %)                | 10 (47.6%)                | 44 (27.2%)                  |     |
| 3.39–33.9 mg/mmol (n, %)            | 2(9.5%)                   | 7 (11.3%)                   |     |
| >33.9 mg/mmol (n, %)                |                           |                             |     |
| Log albumin/creatinine ratio         | 1.50 ± 0.70               | 1.25 ± 0.61                 | 0.085|
| Diabetic Retinopathy (n,%)           | 11 (47.82%)               | 40 (24.40%)                 | 0.018|
| Diabetic Neuropathy (n,%)            | 3(13.04%)                 | 32(19.451)                  | 0.450|
| CACS > 400AU (n, %)                 | 10 (52.63%)               | 31(19.562)                  | 0.001|
| Log CACs (AU)                       | 2.55 ± 0.84               | 2.05 ± 0.78.7              | 0.013|
| AGEs 3rd Tertil (AU)                | 12 (63.15%)               | 39 (26.71%)                 | 0.001|
| AAS (n,%)                           | 6(27.27%)                 | 54 (32,92%)                 | 0.594|
| Statines (n,%)                      | 14 (63.63%)               | 119 (72567%)                | 0.384|
Table 4
Results of the multivariate Cox's regression for predicting a vascular event.

|                                                                 | HR   | CI95%       | p      |
|----------------------------------------------------------------|------|-------------|--------|
| Sex (female)                                                    | 0.35 | 0.15–0.83   | 0.017  |
| Age (y)                                                        | 1.09 | 1.01–1.18   | 0.024  |
| BMI (kg/m2)                                                    | 0.99 | 0.91–1.08   | 0.820  |
| Diabetes duration (y)                                          | 1.04 | 0.99–1.08   | 0.093  |
| Waist (cm)                                                     | 1.01 | 0.98–1.04   | 0.526  |
| Hypertension (yes)                                             | 1.13 | 0.45–2.88   | 0.792  |
| Dyslipedemia (yes)                                             | 0.59 | 0.24–1.44   | 0.244  |
| Insulin treatment (yes)                                        | 2.11 | 0.83–5.36   | 0.116  |
| HbA1c (mmol/mol)                                               | 1.20 | 0.88–1.66   | 0.255  |
| GFR (ml/min)                                                   | 1.02 | 0.99–1.05   | 0.170  |
| Creatinine (mg/dl)                                             | 0.33 | 0.04–2.44   | 0.275  |
| Diabetic Retinopathy (yes)                                     | 2.58 | 1.14–5.85   | 0.023  |
| CACS > 400 AU (yes)                                            | 4.16 | 1.69–10.26  | 0.002  |
| AGEs 3rd Tertil (yes)                                          | 4.68 | 1.83–11.96  | 0.001  |

Discussion

In the present study we confirmed that individuals with type 2 diabetes had significantly more risk of having a vascular event than non-diabetic subjects. Furthermore, we provide evidence that DR and SAF (as a measure of tissue AGE accumulation) are powerful predictors of vascular events in subjects with type 2 diabetes.

We found that patients with type 2 diabetes had significantly more risk of suffering a vascular event than non-diabetic subjects (12.29% VS 1.75%). Consistent with our findings, previous reports have documented that subjects with type 2 diabetes have a higher risk of developing a vascular event and with a worse outcome in comparison with non-diabetic subjects (1, 2).

Previously, we had already provide evidence that DR is an independent predictor of subclinical CVD (21), and SAF was good predictor of a CACs > 400AU (a reliable marker of coronary atherosclerosis) (15). The
current study is important, because we confirm that both, DR and SAF, are not only related to subclinical cardiovascular disease but also are capable of predicting vascular events in type 2 diabetes population.

Several studies had suggested that the burden of microvascular disease is determinant of future cardiovascular risk (18–20). In our study, only DR is a powerful predictor of vascular events in subjects with type 2 diabetes. According with our findings, previous reports have documented an increase in CV risk in patients with DR, mostly in those with advanced DR (26–29). Although the underlying molecular mechanisms linking DR and cardiovascular disease are still a matter of debate, there are notable similarities in their pathophysiology. In this regard, recent evidence indicates that, in individuals with type 2 diabetes, the vasa vasorum (a network of small blood vessels that supply the walls of large blood vessels) present evolutionary changes similar to those observed in the retina: an initial stage in which endothelial dysfunction and loss of capillaries predominate (23), and more advanced stages in which ischemia plays a key role, leading to angiogenesis and inflammation in response to the progressive enlargement of the necrotic core within the plaque (30). This change in plaque phenotype results in a more inflamed and unstable plaque, favoring plaque rupture and a poor outcome of cardiovascular events. Thus, microcirculation represents a “common soil” between DR and vascular event, and would explain why DR is a good predictor of vascular events as we reported.

SAF was also a good predictor of vascular events in subjects with type 2 diabetes. There are multiples studies that reported significant associations between SAF and the development of late diabetic complications (both micro and macrovascular), most of them being cross-sectional studies (31–40). To the best of our knowledge, only two prospective studies have examined the usefulness of SAF as a predictor of CVD (35, 41). Both, supports our data and concluded that SAF is a measure of metabolic burden but it is also strongly associated with the presence of CVD and cardiac mortality, as well as a biomarker of vascular damage before it becomes clinically apparent. Therefore, SAF could be a useful clinical tool to identify diabetic individuals with preclinical vascular damage who have a particularly high risk of developing vascular events. It is important to remark, that our study is the only one that includes exclusively subjects with type 2 diabetes and no history of clinical cardiovascular disease, apparently those with less cardiovascular risk, and yet we have obtained similar results.

Mulder et al. (42) showed that SAF is elevated in acute ST-elevation myocardial infarction compared with healthy controls, and higher values of SAF were related with more risk to die or a new myocardial infarction or heart failure in the following one year. This finding suggests that SAF may play an important role in the progression of atherosclerosis. Basic research has shown that in atherosclerotic plaques AGEs interact with RAGE, resulting in increased production of inflammatory mediators, causing the plaques more vulnerable to rupture (43). Data on the important role of oxidative stress markers in endothelial dysfunction and clinically over coronary artery disease are extensive (44, 45). However, most markers for oxidative stress are not readily available for clinical practice. By contrast, skin AGES are stable and could be non-invasively assessed, thus serving as a reliable biomarker of cardiovascular disease.
In our study, we show that higher values of SAF were independently associated with the presence of macrovascular complications. Most of the classical cardiovascular risk factors such as hypertension, dyslipidemia and HbA1c were not significantly associated with the occurrence of a vascular event. However, this does not mean that they are not influencing the development of vascular events, but just that are currently under control. In fact, we would need biomarkers that inform us regarding long-term deleterious effect than those reflecting a short-term impairment. In this regard, skin AGEs are mainly accumulated in collagen, which has a low turnover and represents hyperglycaemia over a longer time period than HbA1c, so SAF may reflect the impact of oxidative stress and history of hyperglycaemic episodes better than classical risk factors. In fact, SAF is considered as a measure of metabolic memory in subjects with type 2 diabetes.

In addition to DR and SAF, we found that other classical factors such age, male sex and CACs > 400AU also were related with the presence of a vascular event. Age is an important determinant of cardiovascular risk, and it is known that the prevalence of inducible ischemia is significantly higher in type 2 diabetes patients over 65 years old (46). Furthermore, it is well documented that the absolute risk of cardiovascular events is higher in men than women (47). CACs is a well-recognized biomarker myocardial ischemia and a good predictor of cardiovascular events (48, 49). In fact, guidelines recommend that assessment of CACs could be considered in asymptomatic patients with diabetes mellitus who are over the age of 40 (5). However, CACs assessment needs of a CT scan examination, which can be inconvenient and rather expensive for routine practice in subjects with type 2 diabetes.

Our study has several limitations. First our sample was relatively small and the results could have been impacted by variables such as ambient factors or diet not considered in this analysis. Second, and probably the major limitation, was the low rate of vascular events in our population. However, it should be noted that there is a clear trend toward a decrease in events in diabetic subjects in the last 20 years, as reported Rawshani et al. (50). This is probably due to the better management of the chronic patient with diabetes, associated with better comprehensive control of the rest of the cardiovascular risk factors, with greater use of statins and antihypertensive drugs.

In conclusion, this study confirms that patients with type 2 diabetes have significantly more vascular events than non-diabetic subjects. In addition, DR and higher values of SAF are powerful predictors of vascular events in subjects with type 2 diabetes and, therefore, could be included as meaningful variables in stratification risk of cardiovascular disease.

**Abbreviations**

**AGEs** advanced glycation end products, **AU** arbitrary units, **CACs** coronary artery calcium score, **CVD** cardiovascular disease, **DR** Diabetic retinopathy, **HDL** high-density lipoprotein cholesterol, **LDL** low-density lipoprotein cholesterol, **NPDR** non proliferative retinopathy, **PDR** proliferative diabetic retinopathy, **RAGE** receptors for AGEs, **SAF** skin autofluorescence, **SD** standard deviation.
Declarations

Ethics approval and consent to participate.

The study was conducted according to the declaration of Helsinki and was approved by the local ethics committee: Comité Ético de Investigación Clínica del Hospital Universitario de Vall d’Hebron (Ethical Committee for Clinical Research of the Vall d’Hebron University Hospital), with a reference number PR(AG)127/2014. All subjects provided written informed consent before study entry.

Consent for publication: Not applicable.

Data availability. All data relevant to the study are included in the article. The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Competing interests. The authors declare that they have no competing interests

Funding. This research was funded by grants of Spanish Institute of Health (ISCIII) in the setting of Integrative Excellence Projects (PIE 2013/27) and the European Foundation for the Study of Diabetes (EFSD Pilot Research Grant Programme for Innovative Measurement of Diabetes Outcomes). The study funder was not involved in the design of the study

Author Contributions. CH, IF-G, and RS conceived the study concept and design, interpreted data, and contributed to critically revising the manuscript. AP, OS-S, AO-Z, JRM and JRH collected and analyzed data. AP drafted the manuscript. All authors approved the final article. CH, IF-G, and RS obtained funding. RS is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgements. Not applicable

References

1. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. The Lancet. 2006 Jul;368(9529):29–36.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993 Feb;16(2):434–44.
3. American Diabetes Association. 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S86–104.
4. Authors/Task Force Members:. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;252:207–74.

5. Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care. 2015 Sep;38(9):1777–803.

6. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation. 2016 Jun;14(24):2459–502. 133.

7. Ahern J, Grove N, Strand T, Wesche J, Seibert C, Brenneman AT, et al. The impact of the Trial Coordinator in the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes Educ. 1993 Dec;19(6):509–12.

8. Turner RC. The UK. Prospective Diabetes Study. A review. Diabetes Care. 1998 Dec;21(Suppl 3):C35–8.

9. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006 Aug 8;114(6):597–605.

10. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA. 1994 Sep;113(19):8807–11. 91.

11. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001 Feb;44(2):129–46.

12. Meerwaldt R, Graaff R, Oomen PHN, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004 Jul;47(7):1324–30.

13. Mulder DJ, Water TVD, Rutgers HL, Graaff R, Gans RO, Zijlstra F, et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther. 2006 Oct;8(5):523–35.

14. Bos DC, de Ranitz-Greven WL, de Valk HW. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review. Diabetes Technol Ther. 2011 Jul;13(7):773–9.

15. Planas A, Simó-Servat O, Bañeras J, Sánchez M, García E, Ortiz ÁM, et al. Usefulness of skin advanced glycation end products to predict coronary artery calcium score in patients with type 2 diabetes. Acta Diabetol. 2021 May 25.

16. Simó R, Stehouwer CDA, Avogaro A. Diabetic retinopathy: looking beyond the eyes. Diabetologia. 2020 Aug;63(8):1662–4.
17. Pearce I, Simó R, Lövestam-Adrian M, Wong DT, Evans M. Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. Diabetes Obes Metab. 2019 Mar;21(3):467–78.

18. Brownrigg JRW, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO, Holt PJ, et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. 2016 Jul;4(7):588–97.

19. Hanis CL, Chu HH, Lawson K, Hewett-Emmett D, Barton SA, Schull WJ, et al. Mortality of Mexican Americans with NIDDM. Retinopathy and other predictors in Starr County, Texas. Diabetes Care. 1993 Jan;16(1):82–9.

20. Xie J, Ikram MK, Cotch MF, Klein B, Varma R, Shaw JE, et al. Association of Diabetic Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2017 Jun 1;135(6):586–93.

21. Simó R, Bañeras J, Hernández C, Rodríguez-Palomares J, Valente F, Gutierrez L, et al. Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study. BMJ Open Diabetes Res Care. 2019;7(1):e000845.

22. Kurihara O, Takano M, Mizuno K, Shibata Y, Matsushita M, Komiyama H, et al. Impact of Diabetic Retinopathy on Vulnerability of Atherosclerotic Coronary Plaque and Incidence of Acute Coronary Syndrome. Am J Cardiol. 2016 Oct 1;118(7):944–9.

23. Gerstein HC, Nair V, Chaube R, Stoute H, Werstuck G. Dysglycemia and the Density of the Coronary Vasa Vasorum. Diabetes Care. 2019 May;42(5):980–2.

24. Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003 Sep;110(9):1677–82.

25. American College of Cardiology Foundation Task Force on Expert Consensus Documents. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, et al ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010 Jun 8;55(23):2663–99.

26. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2007 Jul;30(7):1742–6.

27. Targher G, Bertolini L, Zenari L, Lippi G, Pichiri I, Zoppini G, et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Diabet Med. 2008 Jan;25(1):45–50.

28. Gerstein HC, Ambrosius WT, Danis R, Ismail-Beigi F, Cushman W, Calles J, et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care. 2013 May;36(5):1266–71.
29. Alonso N, Traveset A, Rubinat E, Ortega E, Alcubierre N, Sanahuja J, et al. Type 2 diabetes-associated carotid plaque burden is increased in patients with retinopathy compared to those without retinopathy. Cardiovasc Diabetol. 2015 Mar 18;14:33.

30. Sedding DG, Boyle EC, Demandt JAF, Sluimer JC, Dutzmann J, Haverich A, et al. Vasa Vasorum Angiogenesis: Key Player in the Initiation and Progression of Atherosclerosis and Potential Target for the Treatment of Cardiovascular Disease. Front Immunol. 2018;9:706.

31. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care. 2006 Dec;29(12):2654–9.

32. Noordzij MJ, Mulder DJ, Oomen PHN, Brouwer T, Jager J, Castro Cabezas M, et al. Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study. Diabet Med. 2012 Dec;29(12):1556–61.

33. Temma J, Matsuhisa M, Horie T, Kuroda A, Mori H, Tamaki M, et al. Non-invasive Measurement of Skin Autofluorescence as a Beneficial Surrogate Marker for Atherosclerosis in Patients with Type 2 Diabetes. J Med Invest. 2015;62(3–4):126–9.

34. Hirano T, Iesato Y, Toriyama Y, Imai A, Chiba D, Murata T. Correlation between diabetic retinopathy severity and elevated skin autofluorescence as a marker of advanced glycation end-product accumulation in type 2 diabetic patients. J Diabetes Complicat. 2014 Oct;28(5):729–34.

35. Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia. 2009 May;52(5):789–97.

36. Tanaka S, Tanaka S, Iimuro S, Yamashita H, Katayama S, Akanuma Y, et al. Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care. 2013 May;36(5):1193–9.

37. Tanaka K, Tani Y, Asai J, Nemoto F, Kusano Y, Suzuki H, et al. Skin autofluorescence is associated with severity of vascular complications in Japanese patients with Type 2 diabetes. Diabet Med. 2012 Apr;29(4):492–500.

38. Yasuda M, Shimura M, Kunikata H, Kanazawa H, Yasuda K, Tanaka Y, et al. Relationship of skin autofluorescence to severity of retinopathy in type 2 diabetes. Curr Eye Res. 2015 Mar;40(3):338–45.

39. Hangai M, Takebe N, Honma H, Sasaki A, Chida A, Nakano R, et al. Association of Advanced Glycation End Products with coronary Artery Calcification in Japanese Subjects with Type 2 Diabetes as Assessed by Skin Autofluorescence. J Atheroscler Thromb. 2016 Oct 1;23(10):1178–87.

40. Bentata R, Cougnard-Grégoire A, Delyfer MN, Delcourt C, Blanco L, Pupier E, et al. Skin autofluorescence, renal insufficiency and retinopathy in patients with type 2 diabetes. J Diabetes Complicat. 2017 Mar;31(3):619–23.

41. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans ROB, et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care. 2007 Jan;30(1):107–12.
42. Mulder DJ, van Haelst PL, Graaff R, Gans RO, Zijlstra F, Smit AJ. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Neth Heart J. 2009 Apr;17(4):162–8.

43. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res. 1998 Mar;37(3):586–600.

44. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001 Nov 27;104(22):2673–8.

45. Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med. 2004 Oct;256(4):308–15.

46. Chaowalit N, Arruda AL, McCully RB, Bailey KR, Pellikka PA. Dobutamine stress echocardiography in patients with diabetes mellitus: enhanced prognostic prediction using a simple risk score. J Am Coll Cardiol. 2006 Mar;7(5):1029–36.

47. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study JAMA. 1988 Dec;16(23):3456–60.

48. Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J. 2006 Mar;27(6):713–21.

49. Elkeles RS, Godsland IF, Feher MD, Rubens MB, Roughton M, Nugara F, et al. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J. 2008 Sep;29(18):2244–51.

50. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson A-M, Miftaraj M, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017 Apr;376(15):1407–18.

**Figures**
Figure 1

Kaplan-Meier analysis predicting vascular event free-survival regarding groups.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- STROBEcheDiabeticretinopathyandskintissue.docx